eCQM Title | Discharged on Statin Medication |
||
---|---|---|---|
eCQM Identifier (Measure Authoring Tool) | 105 | eCQM Version Number | 10.5.000 |
NQF Number | Not Applicable | GUID | 1f503318-bb8d-4b91-af63-223ae0a2328e |
Measurement Period | January 1, 20XX through December 31, 20XX | ||
Measure Steward | The Joint Commission | ||
Measure Developer | The Joint Commission | ||
Endorsed By | None | ||
Description |
Ischemic stroke patients who are prescribed or continuing to take statin medication at hospital discharge |
||
Copyright |
Measure specifications are in the Public Domain LOINC(R) copyright 2004-2020 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2020 International Health Terminology Standards Development Organisation. ICD-10 copyright 2020 World Health Organization. All Rights Reserved. |
||
Disclaimer |
These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The measures and specifications are provided without warranty. |
||
Measure Scoring | Proportion | ||
Measure Type | Process | ||
Stratification |
None |
||
Risk Adjustment |
None |
||
Rate Aggregation |
None |
||
Rationale |
There is an extensive and consistent body of evidence supporting the use of statins for secondary prevention in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD), which includes individuals with ischemic stroke due to large artery atherosclerosis, individuals with ischemic stroke due to intrinsic small vessel disease, and individuals with ischemic stroke not directly due to atherosclerosis but with clinically evident atherosclerotic disease in an uninvolved cerebral or noncerebral bed. Both women and men with clinical ASCVD are at increased risk for recurrent ASCVD and ASCVD death. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men less than or equal to 75 years of age who have clinical ASCVD, unless contraindicated. In patients with clinical ASCVD and a contraindication to high-intensity statin therapy, moderate-intensity therapy should be considered as an alternative if it can be tolerated. In individuals greater than 75 years of age, the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and patient preferences should be considered, and statin therapy individualized based on these considerations (Stone, 2013). |
||
Clinical Recommendation Statement |
For patients with stroke of atherosclerotic origin, intensive lipid lowering therapy with statins should be initiated |
||
Improvement Notation |
Improvement noted as an increase in rate |
||
Reference |
Reference Type: CITATION Reference Text: 'Amarenco, P., Bogousslavsky, J., Callahan, A., III, et al. (2006, August 10). High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 355(6), 549-559. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Biffi, A., Devan, W. J., Anderson, C. D., et al. (2011, May). Statin treatment and functional outcome after ischemic stroke: Case-control and meta-analysis. Stroke, 42(5), 1314-1319. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Centers for Disease Control and Prevention. (2009, May 1). Prevalence and most common causes of disability among adults—United States, 2005. Morbidity and Mortality Weekly Report, 58(16), 421-426. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Chan, P. S., Nallamothu, B. K., Gurm, H. S., et al. (2007, May 8). Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation, 115(18), 2398-2409. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Culver, A. L., Ockene, I. S., Balasubramanian, R., et al. (2012, January 23). Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Archives of Internal Medicine, 172(2), 144-152.' |
||
Reference |
Reference Type: CITATION Reference Text: 'Feher, A., Pusch, G., Koltai, K., et al. (2011, April 14). Statin therapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. International Journal of Cardiology, 148(2), 131-138. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Grundy, S. M., Cleeman, J. I., Merz, C. N., et al. (2004, July 13). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 110(2), 227-239. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Kernan, W. N., Ovbiagele, B., Black, H. R., et al. (2014, May). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 45(7), 2160-2223. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Kostis, W. J., Cheng, J. Q., Dobrzynski, J. M., et al. (2012, February 7). Meta-analysis of statin effects in women versus men. Journal of the American College of Cardiology, 59(6), 572-582.' |
||
Reference |
Reference Type: CITATION Reference Text: 'Lazar, L. D., Pletcher, M. J., Coxson, P. G., et al. (2011, July 12). Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation, 124(2), 146-153.' |
||
Reference |
Reference Type: CITATION Reference Text: 'Mitka, M. (2012, March 7). Some question use of statins to reduce cardiovascular risks in healthy women. JAMA, 307(9), 893-894. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Adults Treatment of High Blood Cholesterol in Adults. (2002, December 17). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)—Final report. Circulation, 106(25), 3143-3421. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Powers, W. J., Rabinstein, A. A., Ackerson, T., et al. (2018, January). 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 49, e44-e47. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Rodriguez-Yanez, M., Agulla, J., Rodriguez-Gonzalez, R., et al. (2008, June). Statins and stroke. Therapeutic Advances in Cardiovascular Disease, 2(3), 157-166. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Roger, V. L., Go, A. S., Lloyd-Jones, D. M., et al. (2012, January 3). Heart disease and stroke statistics—2012 update: A report from the American Heart Association. Circulation, 125(1), e2-e220. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Schellinger, P. D., Bryan, R. N., Caplan, L. R., et al. (2010, July 13). Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 75(2), 177-185.' |
||
Reference |
Reference Type: CITATION Reference Text: 'Squizzato, A., Romualdi, E., Dentali, F., et al. (2011). Statins for acute ischemic stroke. Cochrane Database of Systematic Reviews, 8, CD007551. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Stone, N. J., Robinson, J., Lichtenstein, A. H., et al. (2013, November). Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 11, 1-84. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Van Dis, F. J., Keilson, L. M., Rundell, C. A., et al. (1996, June). Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room. American Journal of Cardiology, 77(14), 1232-1234. ' |
||
Reference |
Reference Type: CITATION Reference Text: 'Weiss, R., Harder, M., & Rowe, J. (2003, May). The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Clinical Therapeutics, 25(5), 1490-1497. ' |
||
Definition |
None |
||
Guidance |
The "Non-elective Inpatient Encounter" value set intends to capture all non-scheduled hospitalizations. This value set is a subset of the "Inpatient Encounter" value set, excluding concepts that specifically refer to elective hospital admissions. Non-elective Inpatient Encounters include emergency, urgent, and unplanned admissions. The "Medication, Discharge" datatype refers to the discharge medication list and is intended to express medications ordered for post-discharge use. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM. |
||
Transmission Format |
TBD |
||
Initial Population |
Inpatient hospitalizations for patients age 18 and older, discharged from inpatient care (non-elective admissions) with a principal diagnosis of ischemic or hemorrhagic stroke and a length of stay less than or equal to 120 days that ends during measurement period |
||
Denominator |
Inpatient hospitalizations for patients with a principal diagnosis of ischemic stroke |
||
Denominator Exclusions |
Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations. Inpatient hospitalizations for patients discharged to another hospital Inpatient hospitalizations for patients who left against medical advice Inpatient hospitalizations for patients who expired Inpatient hospitalizations for patients discharged to home for hospice care Inpatient hospitalizations for patients discharged to a health care facility for hospice care Inpatient hospitalizations for patients with comfort measures documented |
||
Numerator |
Inpatient hospitalizations for patients prescribed or continuing to take statin medication at hospital discharge |
||
Numerator Exclusions |
Not Applicable |
||
Denominator Exceptions |
Inpatient hospitalizations for patients with a reason for not prescribing statin medication at discharge Inpatient hospitalizations for patients with a maximum LDL-c result of less than 70 mg/dL <= 30 days prior to arrival or any time during the hospital stay Inpatient hospitalizations for patients with a statin allergy |
||
Supplemental Data Elements |
For every patient evaluated by this measure also identify payer, race, ethnicity and sex |
TJC."Encounter with Principal Diagnosis and Age"
TJC."Ischemic Stroke Encounter"
TJC."Ischemic Stroke Encounters with Discharge Disposition" union TJC."Encounter with Comfort Measures during Hospitalization"
TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter with "Statin at Discharge" DischargeStatin such that DischargeStatin.authorDatetime during IschemicStrokeEncounter.relevantPeriod
None
( TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter with "Statin Not Given at Discharge" NoDischargeStatin such that NoDischargeStatin.authorDatetime during IschemicStrokeEncounter.relevantPeriod ) union ( TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter with "Statin Allergy" StatinAllergy such that StatinAllergy.prevalencePeriod starts on or before end of IschemicStrokeEncounter.relevantPeriod ) union "Encounter with Max LDL less than 70 mg per dL"
None
TJC."Ischemic Stroke Encounter"
( TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter with "Statin Not Given at Discharge" NoDischargeStatin such that NoDischargeStatin.authorDatetime during IschemicStrokeEncounter.relevantPeriod ) union ( TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter with "Statin Allergy" StatinAllergy such that StatinAllergy.prevalencePeriod starts on or before end of IschemicStrokeEncounter.relevantPeriod ) union "Encounter with Max LDL less than 70 mg per dL"
TJC."Ischemic Stroke Encounters with Discharge Disposition" union TJC."Encounter with Comfort Measures during Hospitalization"
TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter where Max(["Laboratory Test, Performed": "LDL-c"] Ldl where Ldl.resultDatetime during Interval[Global."ToDate"(start of IschemicStrokeEncounter.relevantPeriod - 30 days), end of IschemicStrokeEncounter.relevantPeriod] return Ldl.result as Quantity )< 70 'mg/dL'
TJC."Encounter with Principal Diagnosis and Age"
TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter with "Statin at Discharge" DischargeStatin such that DischargeStatin.authorDatetime during IschemicStrokeEncounter.relevantPeriod
["Patient Characteristic Ethnicity": "Ethnicity"]
["Patient Characteristic Payer": "Payer"]
["Patient Characteristic Race": "Race"]
["Patient Characteristic Sex": "ONC Administrative Sex"]
["Allergy/Intolerance": "Statin Allergen"]
["Medication, Discharge": "Statin Grouper"]
["Medication, Not Discharged": "Statin Grouper"] NoStatinDischarge where NoStatinDischarge.negationRationale in "Medical Reason" or NoStatinDischarge.negationRationale in "Patient Refusal"
"Non Elective Inpatient Encounter" NonElectiveEncounter where exists ( NonElectiveEncounter.diagnoses Diagnosis where Diagnosis.rank = 1 and ( Diagnosis.code in "Hemorrhagic Stroke" or Diagnosis.code in "Ischemic Stroke" ) )
"Ischemic Stroke Encounter" IschemicStrokeEncounter with "Intervention Comfort Measures" ComfortMeasure such that Coalesce(start of Global."NormalizeInterval"(ComfortMeasure.relevantDatetime, ComfortMeasure.relevantPeriod), ComfortMeasure.authorDatetime)during Global."HospitalizationWithObservation" ( IschemicStrokeEncounter )
"All Stroke Encounter" AllStrokeEncounter with ["Patient Characteristic Birthdate": "Birth date"] BirthDate such that Global."CalendarAgeInYearsAt" ( BirthDate.birthDatetime, start of AllStrokeEncounter.relevantPeriod ) >= 18
["Intervention, Order": "Comfort Measures"] union ["Intervention, Performed": "Comfort Measures"]
"Encounter with Principal Diagnosis and Age" EncounterWithAge where exists ( EncounterWithAge.diagnoses Diagnosis where Diagnosis.code in "Ischemic Stroke" and Diagnosis.rank = 1 )
( ( "Ischemic Stroke Encounter" IschemicStrokeEncounter where IschemicStrokeEncounter.dischargeDisposition in "Discharge To Acute Care Facility" or IschemicStrokeEncounter.dischargeDisposition in "Left Against Medical Advice" or IschemicStrokeEncounter.dischargeDisposition in "Patient Expired" or IschemicStrokeEncounter.dischargeDisposition in "Discharged to Home for Hospice Care" or IschemicStrokeEncounter.dischargeDisposition in "Discharged to Health Care Facility for Hospice Care" ) )
["Encounter, Performed": "Non-Elective Inpatient Encounter"] NonElectiveEncounter where Global."LengthInDays" ( NonElectiveEncounter.relevantPeriod ) <= 120 and NonElectiveEncounter.relevantPeriod ends during day of "Measurement Period"
years between ToDate(BirthDateTime)and ToDate(AsOf)
Encounter Visit let ObsVisit: Last(["Encounter, Performed": "Observation Services"] LastObs where LastObs.relevantPeriod ends 1 hour or less on or before start of Visit.relevantPeriod sort by end of relevantPeriod ), VisitStart: Coalesce(start of ObsVisit.relevantPeriod, start of Visit.relevantPeriod), EDVisit: Last(["Encounter, Performed": "Emergency Department Visit"] LastED where LastED.relevantPeriod ends 1 hour or less on or before VisitStart sort by end of relevantPeriod ) return Interval[Coalesce(start of EDVisit.relevantPeriod, VisitStart), end of Visit.relevantPeriod]
difference in days between start of Value and end of Value
if pointInTime is not null then Interval[pointInTime, pointInTime] else if period is not null then period else null as Interval<DateTime>
DateTime(year from Value, month from Value, day from Value, 0, 0, 0, 0, timezoneoffset from Value)
["Patient Characteristic Ethnicity": "Ethnicity"]
["Patient Characteristic Payer": "Payer"]
["Patient Characteristic Race": "Race"]
["Patient Characteristic Sex": "ONC Administrative Sex"]
Measure Set |
eMeasure Stroke (eSTK) |
---|